Evidence map›Paper›PMID 32248335›Full record

ReviewJournal of thrombosis and thrombolysis2020

The role of P2Y12 receptor inhibition in ischemic stroke on microglia, platelets and vascular smooth muscle cells.

Fengyang Li, Dan Xu, Kai Hou, Xue Gou, Yunman Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of thrombosis and thrombolysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Association ofRevista de neurologia · 2026
    Article
  3. Review
  4. [Acta pharmaceutica Sinica. B · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Increased expression of the P2YRenal failure · 2023
    Article
  14. Pleiotropic effects of clopidogrel.Purinergic signalling · 2022
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Fengyang LiState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Dan XuState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Kai HouState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Xue GouState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Yunman LiState Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. yunmanlicpu@163.com.ORCID http://orcid.org/0000-0001-5565-3322
China Pharmaceutical University · CN

Funding

China Pharmaceutical University "Double First-Class" Construction Technology Innovation Team Project CPU2018GY23China Pharmaceutical University "Double First-Class" Construction Technology Innovation Team Project CPU2018GY24Ministry of Science and Technology of China 2016ZX09101031Ministry of Science and Technology of China 2018ZX09301043
6 · The paper itself

Abstract

P2Y12 receptors on platelets have long been the main target of antiplatelet drugs. However, a growing number of studies have revealed that P2Y12 receptor activation on microglia and vascular smooth muscle cells (VSMCs) also aggravates ischemic stroke injury. The proliferation and migration of VSMCs in the vascular wall have important influence on the early lesion of atherosclerosis, which may lead to the origin of cerebral ischemic attack of atherosclerosis. Blockage of cellular P2Y12 receptors could inhibit microglial activation, block formation of platelet-leukocyte aggregates, reduce proinflammatory cytokine levels and suppress migration and proliferation of VSMCs, implying that apart from anti-thrombotic effect, P2Y12 inhibitors have additional neuroprotective, anti-inflammatory and anti-atherosclerotic therapeutic benefits against ischemic stroke. In this review, we will summarize recent advances in studies on P2Y12 receptors and emphatically introduce their significance in microglia, platelets and VSMCs after ischemic stroke, discussing how to exert the beneficial effects of P2Y12 inhibition.

Indexed as

Ischemic StrokeMuscle, Smooth, VascularAnti-Inflammatory AgentsBlood PlateletsHumansMicrogliaNeuroprotective AgentsPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsAnti-Inflammatory AgentsNeuroprotective AgentsPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsIschemic strokeMicrogliaP2Y12 receptorsPlateletsVSMCs

Identifiers

PMID32248335
OpenAlexW3014803069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.